Regulation of TAL1/SCL in T-Cell Leukemia
T 细胞白血病中 TAL1/SCL 的调控
基本信息
- 批准号:10094201
- 负责人:
- 金额:$ 31.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:Acute T Cell LeukemiaAcute leukemiaApoptosisBinding SitesBiological AssayCRISPR/Cas technologyCell NucleusCellsChromatinChromatin LoopChromosomal translocationChromosome 16DNADNA Binding DomainDataDevelopmentDiagnosisDiseaseEctopic ExpressionEnhancersEpigenetic ProcessErythroid CellsFamilyGene Expression RegulationGenetic TranscriptionGenomeHelix-Turn-Helix MotifsHematopoiesisHematopoieticHumanLeadLeukemic CellLinkLymphomaMalignant - descriptorMalignant NeoplasmsMediatingMolecularMusOncogenesOncogenicPathogenesisPatientsPhenotypePlayProcessPrognosisRNARegulationRegulatory ElementRelapseRoleStem Cell DevelopmentStructureT-Cell LeukemiaT-LymphocyteTAL1 geneTestingTherapeuticTranscriptional ActivationTranscriptional RegulationXenograft ModelZinc Fingersacute T-cell lymphoblastic leukemia cellbasecell typechromosome conformation capturegain of function mutationgenome editinghematopoietic differentiationhematopoietic stem cell self-renewalhuman modelinsightleukemialeukemogenesisloss of functionmembernovelpromotersuccesstargeted treatmenttranscription factor
项目摘要
Abstract:
Aberrant activation of TAL1 oncogene is associated with up to 60% of T-cell acute lymphoblastic
leukemia (T-ALL) patients. Its ectopic expression also led to development of leukemia or lymphoma in mice. In
contrast, deletion of TAL1 in T-ALL cells lost leukemic phenotype and induced apoptosis. Furthermore, the
TAL1 expressing T-ALL subtype is associated with poor prognosis and high rate of relapse. These data
suggest that dysregulation of TAL1 oncogene plays an important role in T-ALL leukemogenesis. However, in
normal hematopoiesis, TAL1 is a hematopoietic-specific member of the basic helix-loop-helix family of
transcription factors required for self-renewal of hematopoietic stem cells and the development of all
hematopoietic lineages. Because of its relevance to normal hematopoietic differentiation and T-cell leukemia, it
is critical to know how TAL1 oncogene is differentially activated in normal hematopoietic cells and T-cell acute
leukemia. Understanding of the epigenetic mechanisms governing TAL1 transcriptional regulation will provide
a new insight into epigenetic control of hematopoiesis as well as pathogenesis of T-ALL diseases which may
lead to new strategies for leukemia diagnosis and therapeutic approaches.
We recently found that TAL1 transcription is regulated by different intra- and interchromosomal loops in
normal hematopoietic and leukemia cells, respectively. These intra- and interchromosomal loops alter the cell-
type specific enhancers that interact with the TAL1 promoter. Based on these data, we hypothesize that
repositioning of the TAL1 gene in a close proximity with T-cell specific transcriptionally active loci within
nucleus is essential for aberrantly activating TAL1 oncogene in T-ALL. In this proposal, we will investigate the
underlying molecular mechanisms that connect chromatin loops with transcriptional activation decision of the
TAL1 oncogene as well as elucidate the role of CTCF and enhancer regulatory elements mediated chromatin
interactions in regulation of TAL1 gene during normal hematopoiesis and leukemogenesis. The specific aims
are: 1) Evaluate the role of CTCF mediated genome organization in regulation of enhancer/ promoter
interaction and TAL1 transcription during hematopoiesis and T cell leukemogenesis; 2) Study the molecular
mechanisms by which interchromosomal loops result in aberrant activation of TAL1 oncogene in T-ALL.
摘要:
TAL 1癌基因的异常激活与高达60%的T细胞急性淋巴细胞白血病相关。
白血病(T-ALL)患者。它的异位表达也导致小鼠白血病或淋巴瘤的发展。在
相反,T-ALL细胞中TAL 1的缺失丧失了白血病表型并诱导凋亡。而且
表达TAL 1的T-ALL亚型预后差,复发率高。这些数据
提示TAL 1癌基因调控异常在T-ALL白血病发生中起重要作用。但在
正常造血,TAL 1是造血特异性的基本螺旋-环-螺旋家族成员,
造血干细胞自我更新和所有造血干细胞发育所需的转录因子
造血谱系由于其与正常造血分化和T细胞白血病相关,
了解TAL 1癌基因在正常造血细胞和T细胞急性白血病细胞中的差异激活是至关重要的。
白血病对TAL 1转录调控的表观遗传机制的理解将提供
对造血的表观遗传控制以及T-ALL疾病的发病机制有了新的认识,
从而为白血病诊断和治疗方法带来新的策略。
我们最近发现,TAL 1的转录受不同的染色体内和染色体间环的调控,
正常造血细胞和白血病细胞。这些染色体内和染色体间的环改变了细胞-
与TAL 1启动子相互作用的类型特异性增强子。根据这些数据,我们假设,
将TAL 1基因重新定位在T细胞特异性转录活性位点附近,
细胞核是T-ALL异常激活TAL 1癌基因的关键。在本提案中,我们将调查
潜在的分子机制,连接染色质环与转录激活的决定,
TAL 1癌基因以及阐明CTCF和增强子调控元件介导的染色质的作用
正常造血和白血病发生过程中TAL 1基因调控的相互作用。具体目标
1)评估CTCF介导的基因组组织在增强子/启动子调控中的作用,
2)研究TAL 1基因在造血和T细胞白血病发生中的分子作用,
染色体间环导致T-ALL中TAL 1癌基因异常激活的机制。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Paraspeckle Protein NONO Promotes TAZ Phase Separation in the Nucleus to Drive the Oncogenic Transcriptional Program.
- DOI:10.1002/advs.202102653
- 发表时间:2021-12
- 期刊:
- 影响因子:0
- 作者:Wei Y;Luo H;Yee PP;Zhang L;Liu Z;Zheng H;Zhang L;Anderson B;Tang M;Huang S;Li W
- 通讯作者:Li W
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suming Huang其他文献
Suming Huang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suming Huang', 18)}}的其他基金
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization
lncRNA介导的R环在CTCF边界功能和AML基因组组织中的作用
- 批准号:
10534236 - 财政年份:2021
- 资助金额:
$ 31.51万 - 项目类别:
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization
lncRNA介导的R环在CTCF边界功能和AML基因组组织中的作用
- 批准号:
10384074 - 财政年份:2021
- 资助金额:
$ 31.51万 - 项目类别:
Role of lincRNAs in HSC function and leukemogenesis
lincRNA 在 HSC 功能和白血病发生中的作用
- 批准号:
10312758 - 财政年份:2019
- 资助金额:
$ 31.51万 - 项目类别:
Role of lincRNAs in HSC function and leukemogenesis
lincRNA 在 HSC 功能和白血病发生中的作用
- 批准号:
10064721 - 财政年份:2019
- 资助金额:
$ 31.51万 - 项目类别:
The Role of Long Noncoding RNA in Hematopoiesis
长链非编码 RNA 在造血中的作用
- 批准号:
9523246 - 财政年份:2016
- 资助金额:
$ 31.51万 - 项目类别:
The role of a lincRNA in chromatin structure and hematopoiesis
lincRNA 在染色质结构和造血中的作用
- 批准号:
9126151 - 财政年份:2015
- 资助金额:
$ 31.51万 - 项目类别:
Regulation of insulator function and globin gene expression by USF and associated
USF 及相关产品对绝缘体功能和珠蛋白基因表达的调节
- 批准号:
7837522 - 财政年份:2009
- 资助金额:
$ 31.51万 - 项目类别:
Regulation of insulator function and globin gene expression by USF and associated
USF 及相关产品对绝缘体功能和珠蛋白基因表达的调节
- 批准号:
8213390 - 财政年份:2009
- 资助金额:
$ 31.51万 - 项目类别:
Regulation of insulator function and globin gene expression by USF and associated
USF 及相关产品对绝缘体功能和珠蛋白基因表达的调节
- 批准号:
8034359 - 财政年份:2009
- 资助金额:
$ 31.51万 - 项目类别:
Regulation of insulator function and globin gene expression by USF and associated
USF 及相关产品对绝缘体功能和珠蛋白基因表达的调节
- 批准号:
8431761 - 财政年份:2009
- 资助金额:
$ 31.51万 - 项目类别:
相似海外基金
Targeting Menin in Acute Leukemia with Upregulated HOX Genes
通过上调 HOX 基因靶向急性白血病中的 Menin
- 批准号:
10655162 - 财政年份:2023
- 资助金额:
$ 31.51万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10651543 - 财政年份:2023
- 资助金额:
$ 31.51万 - 项目类别:
Experimental and preclinical modeling of NUP98-rearranged acute leukemia
NUP98重排急性白血病的实验和临床前模型
- 批准号:
10829603 - 财政年份:2023
- 资助金额:
$ 31.51万 - 项目类别:
Rapid Acute Leukemia Genomic Profiling with CRISPR enrichment and Real-time long-read sequencing
利用 CRISPR 富集和实时长读长测序进行快速急性白血病基因组分析
- 批准号:
10839678 - 财政年份:2023
- 资助金额:
$ 31.51万 - 项目类别:
A Systems Epidemiology Approach for Predicting Methotrexate Neurotoxicity in Pediatric Acute Leukemia
预测儿童急性白血病甲氨蝶呤神经毒性的系统流行病学方法
- 批准号:
10655716 - 财政年份:2023
- 资助金额:
$ 31.51万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10435886 - 财政年份:2022
- 资助金额:
$ 31.51万 - 项目类别:
mRNA stability and its impact on hematopoiesis and acute leukemia
mRNA稳定性及其对造血和急性白血病的影响
- 批准号:
10339742 - 财政年份:2022
- 资助金额:
$ 31.51万 - 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
- 批准号:
10505579 - 财政年份:2022
- 资助金额:
$ 31.51万 - 项目类别:
Clonal dynamics and chemoresistance mechanisms of minimal residual disease in acute leukemia
急性白血病微小残留病的克隆动力学和化疗耐药机制
- 批准号:
10351765 - 财政年份:2022
- 资助金额:
$ 31.51万 - 项目类别:
Anti-CD25 Radioimmunotherapy and Total Marrow Irradiation for Treatment of Relapsed and Refractory Acute Leukemia
抗CD25放射免疫治疗和全骨髓照射治疗复发难治性急性白血病
- 批准号:
10576955 - 财政年份:2022
- 资助金额:
$ 31.51万 - 项目类别:














{{item.name}}会员




